prednisone has been researched along with Thymoma in 88 studies
Prednisone: A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.
prednisone : A synthetic glucocorticoid drug that is particularly effective as an immunosuppressant, and affects virtually all of the immune system. Prednisone is a prodrug that is converted by the liver into prednisolone (a beta-hydroxy group instead of the oxo group at position 11), which is the active drug and also a steroid.
Thymoma: A neoplasm originating from thymic tissue, usually benign, and frequently encapsulated. Although it is occasionally invasive, metastases are extremely rare. It consists of any type of thymic epithelial cell as well as lymphocytes that are usually abundant. Malignant lymphomas that involve the thymus, e.g., lymphosarcoma, Hodgkin's disease (previously termed granulomatous thymoma), should not be regarded as thymoma. (From Stedman, 25th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "To examine whether sustained minimal manifestation status (MMS) with complete withdrawal of prednisone is better achieved in thymectomized patients with myasthenia gravis (MG)." | 5.34 | Minimal manifestation status and prednisone withdrawal in the MGTX trial. ( Aban, IB; Amato, AA; Antonini, G; Barboi, AC; Barohn, RJ; Benatar, M; Beydoun, SR; Buckley, C; Cea, G; Chalk, CH; Ciafaloni, E; Conwit, R; Cutter, GR; Dias-Tosta, E; Evoli, A; Heckmann, JM; Jackson, CE; Kaminski, HJ; Katirji, B; King, JO; Kissel, JT; Kostera-Pruszczyk, A; Kuo, HC; Lecky, BRF; Lee, I; Massey, JM; McPherson, T; Minisman, G; Mozaffar, T; Nix, W; Oger, J; Pascuzzi, RM; Pulley, MT; Rivner, MH; Shaibani, AI; Sonett, JR; Ströbel, P; Sussman, J; Tandan, R; Verschuuren, JJG; Vincent, A; Waddington-Cruz, M; Werneck, LC; Witoonpanich, R; Wolfe, GI; Yoshikawa, H, 2020) |
| "To assess the effect of oral corticosteroid therapy on the frequency of development of generalized myasthenia gravis within 2 years, the incidence of thymoma, and the amount of edrophonium needed for a positive test result in patients with ocular myasthenia gravis." | 3.72 | Development of generalized disease at 2 years in patients with ocular myasthenia gravis. ( Homel, P; Kupersmith, MJ; Latkany, R, 2003) |
| "A case of invasive thymoma is presented showing tumour regression after palliative treatment with prednisone." | 3.71 | Regression of invasive thymoma following corticosteroid therapy. ( Mravunac, M; Termeer, A; Visser, FJ, 2001) |
| "In a 43-year-old woman, pancytopenia accompanying thymoma persisted after thymectomy, requiring weekly blood transfusions, and did not respond to prednisone 50 mg/day." | 3.69 | Pancytopenia associated with thymoma resolving after thymectomy and immunosuppressive therapy. Case report. ( De Giacomo, T; Flaishman, I; Rendina, EA; Ricci, C; Venuta, F, 1995) |
| "The authors describe a 62-year-old man with a malignant thymoma that was clinically responsive to oral prednisone." | 3.68 | Nocardiosis after corticosteroid therapy for malignant thymoma. ( Borges, AA; Cohen, MH; Krasnow, SH; Wadleigh, RG, 1993) |
| "One hundred sixteen patients, aged 8 to 82 years, with myasthenia gravis were treated with prednisone, 60 to 80 mg daily, until the onset of improvement, followed by lower-dose alternate-day therapy of several years' duration." | 3.67 | Long-term corticosteroid treatment of myasthenia gravis: report of 116 patients. ( Coslett, HB; Johns, TR; Pascuzzi, RM, 1984) |
| "The authors report the case of a patient with malignant thymoma unresponsive to combination chemotherapy (cyclophosphamide, doxorubicin, vincristine, and prednisone [CHOP] and cisplatin/VP-16) who subsequently achieved clinical response to continuous daily prednisone." | 3.67 | Chemotherapy of malignant thymoma. Case report and review of the literature. ( Hu, E; Levine, J, 1986) |
| " Degree of weakness, duration of illness, use of prednisone, and history of thymectomy or thymoma did not affect the response to intravenous immunoglobulin." | 3.67 | High-dose intravenous immunoglobulin in the management of myasthenia gravis. ( Arsura, EL; Bick, A; Brunner, NG; Grob, D; Namba, T, 1986) |
| "Combination chemotherapy consisting of cyclophosphamide, vincristine, prednisone, and procarbazine (COPP) was administered to 5 patients with invasive lymphoepithelial thymoma." | 3.66 | Combination chemotherapy in invasive thymoma role of COPP. ( Evans, WK; Feld, R; Phillips, MJ; Simpson, WJ; Thompson, DM, 1980) |
| "Thymomas and thymic carcinoma are rare neoplasms." | 2.43 | Current chemotherapy options for thymic epithelial neoplasms. ( Papadopoulos, KP; Thomas, CR, 2005) |
| "It may also be secondary to systemic lupus erythematosus, rheumatoid arthritis, acute severe renal failure, severe nutritional deficiency, or diverse neoplasms, and may remit with treatment of the primary condition." | 2.35 | Diagnosis and treatment of pure red cell aplasia. ( Krantz, SB, 1976) |
| "Thymectomy is considered an effective treatment for myasthenia gravis but the benefit is not immediate." | 1.56 | [Thymectomy in thymomatous and non-thymomatous myasthenia gravis: analysis of a cohort of 46 patients]. ( Alba-Isasi, MT; Arroyo-Tristán, A; Cabrera-Maqueda, JM; Hernández, R; Morales-Ortiz, A, 2020) |
| "His labs were consistent with autoimmune haemolytic anaemia (AIHA), except his reticulocyte count was unexpectedly low." | 1.56 | Double hit: Evans syndrome after malignant thymoma treatment and parvovirus B19 infection. ( Atkinson, TS; Chaaya, G; Jetly-Shridhar, R; Xie, J, 2020) |
| "Thymoma is a rare tumor which represents about 20% of mediastinal tumors." | 1.35 | [Thymoma associated with pure red cell aplasia and Kaposi's sarcoma]. ( Ayoub, A; Ben Amira, S; Fouzi, S; Ketata, W; Msaad, S; Yangui, I, 2009) |
| "Hypereosinophilia has been associated with a wide variety of systemic disorders, including myositis." | 1.33 | Eosinophilia, myositis, and myasthenia gravis associated with a thymoma. ( Avni, I; Buchman, AS; Sadeh, M; Sharabi, Y, 2006) |
| " Remission, pharmacological remission, and marked improvement with reduction in drug dosage were considered good results." | 1.31 | Clinical characteristics and prognosis of myasthenia gravis in older people. ( Batocchi, AP; Di Schino, C; Evoli, A; Minisci, C; Tonali, P, 2000) |
| "Thymomas are rare neoplasms that are usually associated with parathymic syndromes, pure red cell aplasia, myasthenia gravis, hypogammaglobulinaemia and other mainly immunological disorders." | 1.30 | Role of somatostatin analogue-based therapy in unresponsive malignant thymomas. ( Bianco, AR; Lastoria, S; Lombardi, G; Martignetti, A; Montella, L; Palmieri, G; Salvatore, M, 1999) |
| "Because thymoma is a chemosensitive tumor and frequently recurs in patients with Stage II or greater disease, chemotherapy carries a potential survival benefit and should be incorporated into the multimodality approach to prolong disease-free survival." | 1.29 | Thymoma. A retrospective study of 87 cases. ( Cox, JD; Hong, WK; Komaki, R; Lee, JS; Park, HS; Pollack, A; Putnam, JB; Shin, DM, 1994) |
| "Distant metastases and chemotherapy in malignant thymoma are reviewed." | 1.27 | Malignant thymoma with distant metastases: a case report and review of the literature. ( Ichino, Y; Ishikawa, T; Obuchi, M; Suko, K, 1983) |
| "Oral Prednisone was nearly always preferred: alternate-day high single dose (75 to 115 mg) has given good results in most cases even if in some cases a small dose was required in the "off day"; inversely a lower alternate-day or daily dose was often sufficient." | 1.26 | Treatment of myasthenia gravis. Report on 139 patients. ( Crucitti, F; David, P; Evoli, A; Scoppetta, C; Tonali, P; Vaccario, ML, 1979) |
| "Four patients suffering spinal cord compression resulting from epidural metastases were treated with adrenocorticosteroid hormones." | 1.26 | "Disappearing" spinal cord compression: oncolytic effect of glucocorticoids (and other chemotherapeutic agents) on epidural metastases. ( Cvitkovic, E; Howieson, J; Posner, JB, 1977) |
| " Radical excision of the tumor, if possible, and the remaining thymus, high dosage alternate day prednisone, and radiation therapy, if indicated, seem the treatments of choice." | 1.25 | Myasthenia gravis and invasive thymoma: a 20-year experience. ( Brown, WJ; Goldman, AJ; Herrmann, C; Keesey, JC; Mulder, DG, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 43 (48.86) | 18.7374 |
| 1990's | 13 (14.77) | 18.2507 |
| 2000's | 18 (20.45) | 29.6817 |
| 2010's | 9 (10.23) | 24.3611 |
| 2020's | 5 (5.68) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, S | 1 |
| Yang, H | 1 |
| Guo, R | 1 |
| Wang, L | 1 |
| Zhang, Y | 4 |
| Lv, J | 2 |
| Zhao, X | 2 |
| Zhang, J | 2 |
| Fang, H | 2 |
| Zhang, Q | 2 |
| Yang, J | 2 |
| Cui, X | 2 |
| Gao, P | 1 |
| Chang, T | 1 |
| Gao, F | 2 |
| Cabrera-Maqueda, JM | 1 |
| Alba-Isasi, MT | 1 |
| Hernández, R | 1 |
| Arroyo-Tristán, A | 1 |
| Morales-Ortiz, A | 1 |
| Xie, J | 1 |
| Chaaya, G | 1 |
| Jetly-Shridhar, R | 1 |
| Atkinson, TS | 1 |
| Yuen, C | 1 |
| Soliven, B | 1 |
| Rezania, K | 1 |
| Lee, I | 1 |
| Kuo, HC | 1 |
| Aban, IB | 1 |
| Cutter, GR | 1 |
| McPherson, T | 1 |
| Kaminski, HJ | 1 |
| Sussman, J | 1 |
| Ströbel, P | 2 |
| Oger, J | 2 |
| Cea, G | 1 |
| Heckmann, JM | 1 |
| Evoli, A | 5 |
| Nix, W | 1 |
| Ciafaloni, E | 1 |
| Antonini, G | 1 |
| Witoonpanich, R | 1 |
| King, JO | 1 |
| Beydoun, SR | 1 |
| Chalk, CH | 1 |
| Barboi, AC | 1 |
| Amato, AA | 1 |
| Shaibani, AI | 1 |
| Katirji, B | 1 |
| Lecky, BRF | 1 |
| Buckley, C | 1 |
| Vincent, A | 1 |
| Dias-Tosta, E | 1 |
| Yoshikawa, H | 1 |
| Waddington-Cruz, M | 1 |
| Pulley, MT | 1 |
| Rivner, MH | 1 |
| Kostera-Pruszczyk, A | 1 |
| Pascuzzi, RM | 2 |
| Jackson, CE | 1 |
| Verschuuren, JJG | 1 |
| Massey, JM | 1 |
| Kissel, JT | 1 |
| Werneck, LC | 1 |
| Benatar, M | 1 |
| Barohn, RJ | 1 |
| Tandan, R | 3 |
| Mozaffar, T | 1 |
| Conwit, R | 1 |
| Minisman, G | 1 |
| Sonett, JR | 1 |
| Wolfe, GI | 1 |
| Nakamura, S | 1 |
| Kawaguchi, K | 1 |
| Fukui, T | 1 |
| Hakiri, S | 1 |
| Ozeki, N | 1 |
| Mori, S | 1 |
| Goto, M | 1 |
| Hashimoto, K | 1 |
| Ito, T | 1 |
| Yokoi, K | 1 |
| Li, M | 1 |
| Han, J | 1 |
| Ren, L | 1 |
| Li, Q | 1 |
| Du, Y | 1 |
| Weissferdt, A | 1 |
| Moran, CA | 1 |
| Benjamin, B | 1 |
| Zaltzman, R | 1 |
| Shpitz, B | 1 |
| Gordon, CR | 1 |
| Avital, S | 1 |
| Modrego, PJ | 1 |
| Arribas, J | 1 |
| Sudulagunta, SR | 1 |
| Sepehrar, M | 1 |
| Sodalagunta, MB | 1 |
| Settikere Nataraju, A | 1 |
| Bangalore Raja, SK | 1 |
| Sathyanarayana, D | 1 |
| Gummadi, S | 1 |
| Burra, HK | 1 |
| Kirzinger, L | 1 |
| Boy, S | 1 |
| Marienhagen, J | 1 |
| Schuierer, G | 1 |
| Neu, R | 1 |
| Ried, M | 1 |
| Hofmann, HS | 1 |
| Wiebe, K | 1 |
| May, C | 1 |
| Kleylein-Sohn, J | 1 |
| Baierlein, C | 1 |
| Bogdahn, U | 1 |
| Marx, A | 1 |
| Schalke, B | 1 |
| Ketata, W | 1 |
| Fouzi, S | 1 |
| Msaad, S | 1 |
| Ben Amira, S | 1 |
| Yangui, I | 1 |
| Ayoub, A | 1 |
| Rigamonti, A | 1 |
| Lauria, G | 1 |
| Piamarta, F | 1 |
| Fiumani, A | 1 |
| Agostoni, E | 1 |
| Burrough, ER | 1 |
| Myers, RK | 1 |
| Hostetter, SJ | 1 |
| Fox, LE | 1 |
| Bayer, BJ | 1 |
| Felz, CL | 1 |
| Waller, KR | 1 |
| Whitley, EM | 1 |
| Katzberg, HD | 1 |
| Aziz, T | 1 |
| Kupersmith, MJ | 1 |
| Latkany, R | 1 |
| Homel, P | 1 |
| PARRY, EH | 1 |
| KILPATRICK, GS | 1 |
| HARDISTY, RM | 1 |
| ADAMS, JE | 1 |
| KLEIN, JJ | 1 |
| GOTTLIEB, AJ | 1 |
| MONES, RJ | 1 |
| APPEL, SH | 1 |
| OSSERMAN, KE | 1 |
| ROSNER, P | 1 |
| HAUSSER, E | 1 |
| Greenberg, SA | 1 |
| Loehrer, PJ | 1 |
| Wang, W | 1 |
| Johnson, DH | 1 |
| Aisner, SC | 1 |
| Ettinger, DS | 1 |
| Zieliński, M | 1 |
| Kuzdzał, J | 1 |
| Staniec, B | 1 |
| Harazda, M | 1 |
| Nabiałek, T | 1 |
| Pankowski, J | 1 |
| Szlubowski, A | 1 |
| Medoń, J | 1 |
| Tiseo, M | 1 |
| Monetti, F | 1 |
| Ferrarini, M | 1 |
| Serrano, J | 1 |
| Chiaramondia, M | 1 |
| Ardizzoni, A | 1 |
| Papadopoulos, KP | 1 |
| Thomas, CR | 1 |
| Ji, H | 1 |
| Zhang, WY | 1 |
| Liu, WP | 1 |
| Li, GD | 1 |
| Li, L | 1 |
| Avni, I | 1 |
| Sharabi, Y | 1 |
| Sadeh, M | 1 |
| Buchman, AS | 1 |
| Yamato, H | 1 |
| Tsutsumi, Y | 1 |
| Ehira, N | 1 |
| Kanamori, H | 1 |
| Shimoyama, N | 1 |
| Tanaka, J | 1 |
| Imamura, M | 1 |
| Asaka, M | 1 |
| Hasegawa, T | 1 |
| Masauzi, N | 1 |
| van der Marel, J | 1 |
| Pahlplatz, PV | 1 |
| Steup, WH | 1 |
| Hendriks, ER | 1 |
| Fattorossi, A | 1 |
| Battaglia, A | 1 |
| Buzzonetti, A | 1 |
| Minicuci, G | 1 |
| Riso, R | 1 |
| Peri, L | 1 |
| Scambia, G | 1 |
| Ezzie, ME | 1 |
| Janssen, WJ | 1 |
| O'Brien, JM | 1 |
| Fox, CC | 1 |
| Schwarz, MI | 1 |
| Schumm, F | 1 |
| Brinkmann, A | 1 |
| Fateh-Moghadam, A | 1 |
| Almog, C | 2 |
| Horowitz, M | 1 |
| Burke, M | 1 |
| Ichino, Y | 1 |
| Obuchi, M | 1 |
| Suko, K | 1 |
| Ishikawa, T | 1 |
| Coslett, HB | 1 |
| Johns, TR | 1 |
| Tonali, P | 3 |
| Scoppetta, C | 2 |
| David, P | 2 |
| Daugaard, G | 1 |
| Hansen, HH | 1 |
| Rørth, M | 1 |
| Evans, WK | 1 |
| Thompson, DM | 1 |
| Simpson, WJ | 1 |
| Feld, R | 1 |
| Phillips, MJ | 1 |
| Park, HS | 1 |
| Shin, DM | 1 |
| Lee, JS | 1 |
| Komaki, R | 1 |
| Pollack, A | 1 |
| Putnam, JB | 1 |
| Cox, JD | 1 |
| Hong, WK | 1 |
| Kaseda, S | 1 |
| Horinouchi, H | 1 |
| Kato, R | 1 |
| Kobayashi, K | 1 |
| Borges, AA | 1 |
| Krasnow, SH | 1 |
| Wadleigh, RG | 1 |
| Cohen, MH | 1 |
| De Giacomo, T | 1 |
| Rendina, EA | 1 |
| Venuta, F | 1 |
| Flaishman, I | 1 |
| Ricci, C | 1 |
| Palmieri, G | 3 |
| Lastoria, S | 3 |
| Colao, A | 1 |
| Vergara, E | 1 |
| Varrella, P | 1 |
| Biondi, E | 1 |
| Selleri, C | 1 |
| Catalano, L | 1 |
| Lombardi, G | 2 |
| Bianco, AR | 2 |
| Salvatore, M | 2 |
| Beekman, R | 1 |
| Kuks, JB | 1 |
| Oosterhuis, HJ | 1 |
| Rennenberg, RJ | 1 |
| Pauwels, P | 1 |
| Vlasveld, LT | 1 |
| Kodama, K | 1 |
| Doi, O | 1 |
| Higashiyama, M | 1 |
| Yokouchi, H | 1 |
| Yasuda, T | 1 |
| Funai, H | 1 |
| Fuxiang, G | 1 |
| Beutner, EH | 1 |
| Montella, L | 2 |
| Martignetti, A | 1 |
| Herrmann, DN | 1 |
| Blaivas, M | 1 |
| Wald, JJ | 1 |
| Feldman, EL | 1 |
| Batocchi, AP | 1 |
| Minisci, C | 1 |
| Di Schino, C | 1 |
| Termeer, A | 1 |
| Visser, FJ | 1 |
| Mravunac, M | 1 |
| Crucitti, F | 1 |
| Vaccario, ML | 1 |
| Dawkins, RL | 1 |
| Posner, JB | 1 |
| Howieson, J | 1 |
| Cvitkovic, E | 1 |
| Pik, A | 1 |
| Weisberg, D | 1 |
| Herczeg, E | 1 |
| Kurstjens, R | 1 |
| Haanen, C | 1 |
| Shellito, J | 1 |
| Khandekar, JD | 1 |
| McKeever, WP | 1 |
| Vick, NA | 1 |
| Krantz, SB | 3 |
| Waldmann, TA | 1 |
| Broder, S | 1 |
| Krakauer, R | 1 |
| MacDermott, RP | 1 |
| Durm, M | 1 |
| Goldman, C | 1 |
| Meade, B | 1 |
| Goldman, AJ | 2 |
| Hermann, C | 1 |
| Keesey, J | 1 |
| Mulder, DG | 2 |
| Brown, WJ | 2 |
| Herrmann, C | 1 |
| Keesey, JC | 1 |
| Doll, DC | 1 |
| Landreneau, RJ | 1 |
| List, AF | 1 |
| Koopman, WJ | 1 |
| Taylor, R | 2 |
| DiCostanzo, DP | 2 |
| Sharma, K | 2 |
| Fries, T | 2 |
| Roberts, J | 2 |
| Ramon, P | 2 |
| Wallaert, B | 2 |
| Lemaître, L | 1 |
| Fournier, E | 1 |
| Rémy, J | 1 |
| Bart, F | 1 |
| Gosselin, B | 2 |
| Tonnel, AB | 1 |
| Wurtz, A | 1 |
| Chambon, JP | 1 |
| Göldel, N | 2 |
| Böning, L | 2 |
| Fredrik, A | 1 |
| Hölzel, D | 1 |
| Hartenstein, R | 1 |
| Wilmanns, W | 2 |
| Hu, E | 1 |
| Levine, J | 1 |
| Frederik, A | 1 |
| Arsura, EL | 1 |
| Bick, A | 1 |
| Brunner, NG | 1 |
| Namba, T | 1 |
| Grob, D | 1 |
| Donovan, PJ | 1 |
| Foley, JF | 1 |
| Tominaga, S | 1 |
| Kondo, M | 1 |
| Ando, Y | 1 |
| Yamashita, S | 1 |
| Uematsu, M | 1 |
| Shigematsu, N | 1 |
| Nishiguchi, I | 1 |
| Hashimoto, S | 1 |
| MacKechnie, HL | 1 |
| Squires, AH | 1 |
| Platts, M | 1 |
| Pruzanski, W | 1 |
| Tan, RS | 1 |
| River, GL | 1 |
| Selecky, PA | 1 |
| Ziment, I | 1 |
| Krain, LS | 1 |
| Bierman, SM | 1 |
| Vasavada, PJ | 1 |
| Bournigal, LJ | 1 |
| Reynolds, RW | 1 |
| Green, JD | 1 |
| Forman, WH | 1 |
| Doll, R | 1 |
| Kinlen, L | 1 |
| Dawson, MA | 1 |
| Böttcher, D | 1 |
| Maas, D | 1 |
| Wendt, F | 2 |
| Schubothe, H | 2 |
| Safdar, SH | 1 |
| Brown, EB | 1 |
| Doyen, A | 1 |
| Schoop, W | 1 |
| Hunstein, W | 1 |
| Fliedner, TM | 1 |
| Wedler, HW | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multi-Center, Single-Blind, Randomized Study Comparing Thymectomy to No Thymectomy in Non-Thymomatous Myasthenia Gravis (MG) Patients Receiving Prednisone[NCT00294658] | Phase 3 | 126 participants (Actual) | Interventional | 2006-06-30 | Completed | ||
| Efficacy of Medical Treatment With Octreotide in Patients With Primary Inoperable Thymoma to Reduce Tumor Size[NCT00332969] | Phase 2 | 25 participants (Actual) | Interventional | 2005-09-30 | Completed | ||
| Phase II Study of Octreotide Treatment of Advanced, Recurrent Thymoma[NCT00003283] | Phase 2 | 38 participants (Anticipated) | Interventional | 1998-10-13 | Completed | ||
| Phase 1-2 Pilot Study of Rituximab (Rituxan) in Refractory Myasthenia Gravis.[NCT00619671] | Phase 1/Phase 2 | 10 participants (Anticipated) | Interventional | 2004-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00294658)
Timeframe: baseline to 3 years
| Intervention | participants (Number) |
|---|---|
| Thymectomy Plus Prednisone | 11 |
| Prednisone Alone | 28 |
Number of patients with MG exacerbation: Thymectomy plus prednisone=6 (out of 66); Prednisone alone=17 (out of 60) (NCT00294658)
Timeframe: baseline to 2 years
| Intervention | days (Mean) |
|---|---|
| Thymectomy Plus Prednisone | 5.5 |
| Prednisone Alone | 26.4 |
Number of patients with MG exacerbation: Thymectomy plus prednisone=6 (out of 66); Prednisone alone=22 (out of 60) (NCT00294658)
Timeframe: baseline to 3 years
| Intervention | days (Mean) |
|---|---|
| Thymectomy Plus Prednisone | 8.7 |
| Prednisone Alone | 22.5 |
Number who had hospitalization: Thymectomy plus prednisone n=15 (out of 66); Prednisone alone n=31 (out of 60) (NCT00294658)
Timeframe: baseline to 3 years
| Intervention | days (Mean) |
|---|---|
| Thymectomy Plus Prednisone | 8.4 |
| Prednisone Alone | 19.2 |
(NCT00294658)
Timeframe: baseline to 3 years
| Intervention | participants (Number) |
|---|---|
| Thymectomy Plus Prednisone | 11 |
| Prednisone Alone | 23 |
Number of participant who experienced at least one serious adverse events over 3 years: Thymectomy plus prednisone n=25 (out of 66); Prednisone alone n=33 (out of 60) (NCT00294658)
Timeframe: baseline to 3 years
| Intervention | participants (Number) |
|---|---|
| Thymectomy Plus Prednisone | 25 |
| Prednisone Alone | 33 |
Number of participant who experienced at least one serious adverse events over 3 years: Thymectomy plus prednisone n=25 (out of 66); Prednisone alone n=33 (out of 60) (NCT00294658)
Timeframe: baseline to 3 years
| Intervention | events (Number) |
|---|---|
| Thymectomy Plus Prednisone | 48 |
| Prednisone Alone | 93 |
For each participant who took azathioprine, we penalized them by taking the maximum dose of prednisone before azathioprine was added. We then applied the same method to compute the time-weighted alternative day prednisone dose from baseline, month 3, 4, 6 and every 3 months through 36 months. (NCT00294658)
Timeframe: baseline, month 3, 4, 6 and every 3 months through 36 months
| Intervention | mg (Mean) |
|---|---|
| Thymectomy Plus Prednisone | 34.4 |
| Prednisone Alone | 64.4 |
For each participant who took azathioprine, we penalized them by taking the prednisone dose at the time azathioprine commenced. We then applied the same method to compute the time-weighted alternative day prednisone dose from baseline, month 3, 4, 6 and every 3 months through 36 months. (NCT00294658)
Timeframe: baseline, month 1 , 2 , 3, 4, 6 and every 3 months through 36 months
| Intervention | mg (Mean) |
|---|---|
| Thymectomy Plus Prednisone | 33.3 |
| Prednisone Alone | 57.9 |
(NCT00294658)
Timeframe: baseline to 3 years
| Intervention | participants (Number) |
|---|---|
| Thymectomy Plus Prednisone | 10 |
| Prednisone Alone | 9 |
Participants reported alternate-day prednisone dose (mg) intake from baseline through withdrawn or completed 3 years follow up. The prednisone dosages had been weighted over the days of reporting period. (NCT00294658)
Timeframe: baseline, month 1 , 2 , 3, 4, 6 and every 3 months through 36 months
| Intervention | mg (Mean) |
|---|---|
| Thymectomy Plus Prednisone | 32 |
| Prednisone Alone | 54 |
MG Activity of Daily Living total scores range from 0 to 24, with the lower scores indicating better daily living quality of life. (NCT00294658)
Timeframe: baseline, month 4, 6 and every 3 months through 36 months
| Intervention | units on a scale (Mean) |
|---|---|
| Thymectomy Plus Prednisone | 2.24 |
| Prednisone Alone | 3.41 |
Physicians reported prescribed alternate-day prednisone dose (mg) intake from baseline through withdrawn or completed 3 years follow up. The prescribed prednisone dosages had been weighted over the days of reporting period. (NCT00294658)
Timeframe: baseline-day 20, month 1,2, 3, 4, 6 and every 3 months through 36 months
| Intervention | mg (Mean) |
|---|---|
| Thymectomy Plus Prednisone | 34.3 |
| Prednisone Alone | 55.6 |
Myasthenia Gravis (QMG) test. QMG total scores range from 0 to 39 for a given visit, with higher scores indicating more severe disease. The time weighted average is a calculation that provides an integrated measure of the outcome over the time of followup. The denominator that was used to compute the time-weighted average for the Quantitative Myasthenia Gravis (QMG) score and the prednisone dose was the number of days from randomization to the last visit. Computations used the trapezoidal method where in the QMG score is multiplied by the number of days at this level from one visit to the next and added up over the entire followup experience and divided by the total number of days from randomization. (NCT00294658)
Timeframe: baseline, month 3, 4, 6 and every 3 months through 36 months
| Intervention | units on a scale (Mean) |
|---|---|
| Thymectomy Plus Prednisone | 6.15 |
| Prednisone Alone | 8.99 |
(NCT00294658)
Timeframe: baseline to 3 years
| Intervention | participants (Number) | |||||
|---|---|---|---|---|---|---|
| Life-threatening | Disability or incapacity | Medical or surgical intervention | Death | Complication due to thytmectomy | Hospitalization | |
| Prednisone Alone | 7 | 2 | 5 | 1 | 0 | 31 |
| Thymectomy Plus Prednisone | 1 | 8 | 9 | 0 | 1 | 15 |
(NCT00294658)
Timeframe: baseline to 2 years and baseline to 3 years
| Intervention | participants (Number) | |
|---|---|---|
| Months 0-24 | Months 0-36 | |
| Prednisone Alone | 17 | 22 |
| Thymectomy Plus Prednisone | 6 | 6 |
Number of participants who were in minimal manifestation status at month 12, 24 and 36. (NCT00294658)
Timeframe: Month 12, 24 and 36
| Intervention | participants (Number) | ||
|---|---|---|---|
| Month 12 | Month 24 | Month 36 | |
| Prednisone Alone | 20 | 20 | 24 |
| Thymectomy Plus Prednisone | 41 | 39 | 39 |
Number who had hospitalization: Thymectomy plus prednisone n=15 (out of 66); Prednisone alone n=31 (out of 60) (NCT00294658)
Timeframe: baseline to 3 years
| Intervention | events (Number) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Gastrointestinal disorder | Hepatobiliary disorder | Infection or infestation | Injury, poisoning, or procedure complication | Metabolism or nutrition disorder | Nervous system disorder | Respiratory, thoracic, or mediastinal disorder | Surgical or medical procedure | Vascular disorder | |
| Prednisone Alone | 2 | 1 | 7 | 0 | 0 | 22 | 2 | 7 | 1 |
| Thymectomy Plus Prednisone | 2 | 0 | 4 | 2 | 1 | 8 | 1 | 0 | 0 |
Range from 0 to 100, the higher the mental component value, the better the mental health. (NCT00294658)
Timeframe: Month 0, Month 12, Month 24 and Month 36
| Intervention | units on a scale (Median) | |||
|---|---|---|---|---|
| Month 0 | Month 12 | Month 24 | Month 36 | |
| Prednisone Alone | 46.2 | 41.7 | 46.7 | 48.2 |
| Thymectomy Plus Prednisone | 49.1 | 39.1 | 49.9 | 51.7 |
Range from 0 to 100, the higher the physical component value, the better the mental health. (NCT00294658)
Timeframe: Month 0, Month 12, Month 24 and Month 36
| Intervention | units on a scale (Median) | |||
|---|---|---|---|---|
| Month 0 | Month 12 | Month 24 | Month 36 | |
| Prednisone Alone | 37.9 | 44.4 | 43.0 | 44.2 |
| Thymectomy Plus Prednisone | 41.4 | 48.4 | 50.3 | 48.2 |
Participants reported alternate-day prednisone dose (mg) intake from baseline through withdrawn or completed 3 years follow up. The prednisone dosages had been weighted over the days of reporting period. (NCT00294658)
Timeframe: baseline, month 3, 4, 6 and every 3 months through 36 months
| Intervention | mg (Mean) | |
|---|---|---|
| Not prednisone naïve | Prednisone naïve | |
| Prednisone Alone | 56 | 45 |
| Thymectomy Plus Prednisone | 35 | 25 |
Participants reported alternate-day prednisone dose (mg) intake from baseline through withdrawn or completed 3 years follow up. The prednisone dosages had been weighted over the days of reporting period. (NCT00294658)
Timeframe: baseline, month 3, 4, 6 and every 3 months through 36 months
| Intervention | mg (Mean) | |
|---|---|---|
| Female | Male | |
| Prednisone Alone | 54 | 55 |
| Thymectomy Plus Prednisone | 33 | 31 |
Participants reported alternate-day prednisone dose (mg) intake from baseline through withdrawn or completed 3 years follow up. The prednisone dosages had been weighted over the days of reporting period. (NCT00294658)
Timeframe: baseline, month 3, 4, 6 and every 3 months through 36 months
| Intervention | mg (Mean) | |
|---|---|---|
| Age (Years) at Disease Onset < 40 | Age (Years) at Disease Onset ≥ 40 | |
| Prednisone Alone | 55 | 49 |
| Thymectomy Plus Prednisone | 35 | 27 |
Myasthenia Gravis (QMG) test. QMG total scores range from 0 to 39 for a given visit, with higher scores indicating more severe disease. (NCT00294658)
Timeframe: baseline, month 3, 4, 6 and every 3 months through 36 months
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Age (years) at Disease Onset < 40 | Age (years) at Disease Onset ≥ 40 | |
| Prednisone Alone | 9.60 | 7.85 |
| Thymectomy Plus Prednisone | 6.50 | 5.33 |
Myasthenia Gravis (QMG) test. QMG total scores range from 0 to 39 for a given visit, with higher scores indicating more severe disease. (NCT00294658)
Timeframe: baseline, month 3, 4, 6 and every 3 months through 36 months
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Not prednisone naïve | Prednisone naïve | |
| Prednisone Alone | 9.10 | 8.84 |
| Thymectomy Plus Prednisone | 6.30 | 5.66 |
Myasthenia Gravis (QMG) test. QMG total scores range from 0 to 39 for a given visit, with higher scores indicating more severe disease. (NCT00294658)
Timeframe: baseline, month 3, 4, 6 and every 3 months through 36 months
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Female | Male | |
| Prednisone Alone | 9.73 | 7.45 |
| Thymectomy Plus Prednisone | 6.47 | 5.23 |
MG Activity of Daily Living total scores range from 0 to 24 by visit, with the lower scores indicating better daily living quality of life. (NCT00294658)
Timeframe: Month 12, 24, and 36
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Month 12 | Month 24 | Month 36 | |
| Prednisone Alone | 3.33 | 3.11 | 2.69 |
| Thymectomy Plus Prednisone | 1.92 | 2.02 | 2.14 |
Treatment associated complications measured complications occurred by myasthenia gravis patients. Report number of participant with at least one complications by each visit. (NCT00294658)
Timeframe: Month 0, 1, 2, 3, 4 then every 3 months through Month 36
| Intervention | Participants (Count of Participants) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Month 0 | Month 1 | Month 2 | Month 3 | Month 4 | Month 6 | Month 9 | Month 12 | Month 15 | Month 18 | Month 21 | Mpnth 24 | Mpnth 27 | Month 30 | Month 33 | Month 36 | |
| Prednisone Alone | 17 | 15 | 20 | 16 | 23 | 22 | 26 | 28 | 24 | 24 | 20 | 23 | 17 | 19 | 23 | 23 |
| Thymectomy Plus Prednisone | 22 | 15 | 22 | 21 | 23 | 21 | 37 | 35 | 29 | 28 | 22 | 28 | 25 | 23 | 24 | 23 |
Treatment associated symptoms measured myasthenia gravis symptoms such as back pain and/or bruises. Report number of participant with at least one treatment associated symptoms by each visit. (NCT00294658)
Timeframe: Month 0, 1, 2, 3, 4 then every 3 months through Month 36
| Intervention | Participants (Count of Participants) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Month 0 | Month 1 | Month 2 | Month 3 | Month 4 | Month 6 | Month 9 | Month 12 | Month 15 | Month 18 | Month 21 | Mpnth 24 | Mpnth 27 | Month 30 | Month 33 | Month 36 | |
| Prednisone Alone | 53 | 52 | 53 | 54 | 54 | 53 | 50 | 52 | 51 | 51 | 50 | 51 | 50 | 50 | 48 | 47 |
| Thymectomy Plus Prednisone | 63 | 55 | 61 | 60 | 59 | 60 | 59 | 56 | 56 | 52 | 52 | 52 | 50 | 49 | 51 | 49 |
6 reviews available for prednisone and Thymoma
| Article | Year |
|---|---|
Current chemotherapy options for thymic epithelial neoplasms.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Cisplatin; Combined Modality Therapy; Diseas | 2005 |
A case of thymoma-associated autoimmune haemolytic anaemia.
Topics: Administration, Oral; Anemia, Hemolytic, Autoimmune; Antineoplastic Agents, Hormonal; Coombs Test; F | 1997 |
[Thymoma and somatostatin analogs. Biology, diagnostic and clinical practice].
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Humans; Indium Radi | 2001 |
Diagnosis and treatment of pure red cell aplasia.
Topics: Acute Kidney Injury; Anemia, Aplastic; Antilymphocyte Serum; Arthritis, Rheumatoid; Blood Cell Count | 1976 |
Metastasizing thymoma and myasthenia gravis. Favorable response to glucocorticoids after failed chemotherapy and radiation therapy.
Topics: Drug Administration Schedule; Female; Humans; Middle Aged; Myasthenia Gravis; Prednisone; Pyridostig | 1990 |
Annotation: pure red cell aplasia.
Topics: Adult; Anemia, Aplastic; Animals; Antibodies, Antinuclear; Antigen-Antibody Complex; Bone Marrow; Bo | 1973 |
3 trials available for prednisone and Thymoma
| Article | Year |
|---|---|
Minimal manifestation status and prednisone withdrawal in the MGTX trial.
Topics: Adolescent; Adult; Animals; Combined Modality Therapy; Female; Humans; Immunosuppressive Agents; Mal | 2020 |
Octreotide LAR and Prednisone as Neoadjuvant Treatment in Patients with Primary or Locally Recurrent Unresectable Thymic Tumors: A Phase II Study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Delayed-Action Prepa | 2016 |
Octreotide alone or with prednisone in patients with advanced thymoma and thymic carcinoma: an Eastern Cooperative Oncology Group Phase II Trial.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Carcin | 2004 |
79 other studies available for prednisone and Thymoma
| Article | Year |
|---|---|
Antibodies to Full-Length Agrin Protein in Chinese Patients With Myasthenia Gravis.
Topics: Age of Onset; Aged; Agrin; Autoantibodies; Autoantigens; China; Cholinesterase Inhibitors; Female; G | 2021 |
[Thymectomy in thymomatous and non-thymomatous myasthenia gravis: analysis of a cohort of 46 patients].
Topics: Acetylcholine; Adolescent; Adult; Aged; Autoantibodies; Autoimmune Diseases; Combined Modality Thera | 2020 |
Double hit: Evans syndrome after malignant thymoma treatment and parvovirus B19 infection.
Topics: Adult; Anemia, Hemolytic, Autoimmune; Diagnosis, Differential; Erythrocyte Transfusion; Glucocortico | 2020 |
ATM mutation in a patient with thymoma-associated myasthenia gravis.
Topics: Ataxia Telangiectasia Mutated Proteins; Breast Neoplasms; Carcinoma, Ductal, Breast; Cholinesterase | 2020 |
Multimodality therapy for thymoma patients with pleural dissemination.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; | 2019 |
Clinical analysis of Chinese anti-low-density-lipoprotein-receptor-associated protein 4 antibodies in patients with myasthenia gravis.
Topics: Adolescent; Adult; Age Factors; Aged; Autoantibodies; Child; Child, Preschool; China; Cholinesterase | 2019 |
The impact of neoadjuvant chemotherapy on the histopathological assessment of thymomas: a clinicopathological correlation of 28 cases treated with a similar regimen.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Cycl | 2013 |
Presacral Mass Discovered during Pregnancy followed by Myasthenia Gravis.
Topics: Adult; Azathioprine; Castleman Disease; Cholinesterase Inhibitors; Female; Humans; Immunosuppressive | 2015 |
Spontaneous resolution of a mediastinal mass in a woman with myasthenia gravis.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Azathioprine; Cholinesterase Inhib | 2018 |
Refractory myasthenia gravis - clinical profile, comorbidities and response to rituximab.
Topics: Adult; Age of Onset; Aged; Anti-Inflammatory Agents; Antibodies; Diabetes Complications; Diabetes Me | 2016 |
[Thymoma associated with pure red cell aplasia and Kaposi's sarcoma].
Topics: Anti-Inflammatory Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Pr | 2009 |
Thymoma-associated myasthenia gravis without acetylcholine receptor antibodies.
Topics: Action Potentials; Anti-Inflammatory Agents; Autoantibodies; Azathioprine; Electric Stimulation; Evo | 2011 |
Amyloid deposition in 2 feline thymomas.
Topics: Amyloid; Animals; Cat Diseases; Cats; Female; Immunosuppressive Agents; Male; Mediastinal Neoplasms; | 2012 |
In myasthenia gravis, clinical and immunological improvement post-thymectomy segregate with results of in vitro antibody secretion by immunocytes.
Topics: Adult; Anti-Inflammatory Agents; Autoantibodies; Cell Culture Techniques; Cholinesterase Inhibitors; | 2002 |
Development of generalized disease at 2 years in patients with ocular myasthenia gravis.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Antibodi | 2003 |
Red-cell aplasia and benign thymoma; studies on a case responding to prednisone.
Topics: Anemia; Anemia, Aplastic; Humans; Prednisone; Red-Cell Aplasia, Pure; Thymoma | 1959 |
LEUKEMOGENIC THYMOMA: REPORT OF A UNIQUE CASE.
Topics: Adolescent; Bone Marrow; Chlorothiazide; Humans; Leukemia; Mediastinal Neoplasms; Neoplasm Metastasi | 1963 |
THYMOMA AND POLYMYOSITIS. ONSET OF MYASTHENIA GRAVIS AFTER THYMECTOMY: REPORT OF TWO CASES.
Topics: Aspartate Aminotransferases; Autoimmune Diseases; Biopsy; Cortisone; Electromyography; Humans; Myast | 1964 |
[PURE ERYTHROBLASTOPENIA. APROPOS OF A CASE OF PRIMARY PURE ERYTHROBLASTOPENIA IN AN ADULT].
Topics: Anemia; Anemia, Aplastic; Classification; Diagnosis, Differential; Geriatrics; Humans; Prednisone; R | 1964 |
Acquired rippling muscle disease with myasthenia gravis.
Topics: Adult; Alopecia Areata; Antineoplastic Agents; Electromyography; Humans; Male; Muscle Contraction; M | 2004 |
Safety for preoperative use of steroids for transsternal thymectomy in myasthenia gravis.
Topics: Adult; Female; Humans; Male; Morbidity; Myasthenia Gravis; Postoperative Complications; Prednisone; | 2004 |
CASE 1. Complete remission to corticosteroids in an octreotide-refractory thymoma.
Topics: Antineoplastic Agents, Hormonal; Drug Therapy, Combination; Female; Humans; Middle Aged; Octreotide; | 2005 |
[Mediastinal (thymic) large B-cell lymphoma: three cases reports].
Topics: Adolescent; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Diagnosis, Diffe | 2005 |
Eosinophilia, myositis, and myasthenia gravis associated with a thymoma.
Topics: Aged; Anti-Inflammatory Agents; Blood Cell Count; Cholinesterase Inhibitors; Eosinophilia; Eye Movem | 2006 |
A case of non-Hodgkin's lymphoma and invasive thymoma treated with R-CHOP therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; Lymphoma, B-C | 2006 |
Thymoma with paraneoplastic syndromes, Good's syndrome, and pure red cell aplasia.
Topics: Agammaglobulinemia; Biopsy, Needle; Follow-Up Studies; Humans; Immunohistochemistry; Male; Middle Ag | 2007 |
Thymopoiesis, regulatory T cells, and TCRVbeta expression in thymoma with and without myasthenia gravis, and modulatory effects of steroid therapy.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aged; Antigens, CD; CD3 Complex; CD4 Lymphocyte Count; C | 2008 |
Clinical problem-solving. Failure to respond--a 52-year-old man presented to his primary care physician with dyspnea and cough.
Topics: Anti-Bacterial Agents; Bacteremia; Cough; Diagnosis, Differential; Dyspnea; Glucocorticoids; Humans; | 2008 |
[Antibody-controlled cytostatic therapy of malignant thymoma with concomitant myasthenia gravis].
Topics: Acetylcholine; Antibodies; Antineoplastic Combined Chemotherapy Protocols; Azathioprine; Cyclophosph | 1984 |
Steroid therapy in inappropriate secretion of antidiuretic hormone due to malignant thymoma.
Topics: Female; Humans; Inappropriate ADH Syndrome; Middle Aged; Neoplasm Recurrence, Local; Prednisone; Rad | 1983 |
Malignant thymoma with distant metastases: a case report and review of the literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Cyclophosphamide; F | 1983 |
Long-term corticosteroid treatment of myasthenia gravis: report of 116 patients.
Topics: Adolescent; Adult; Age Factors; Aged; Child; Drug Administration Schedule; Female; Humans; Male; Mid | 1984 |
Myasthenia gravis in the elderly: report of 37 cases.
Topics: Aged; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myasthenia Gravis; Prednisone; Pyridosti | 1983 |
Combination chemotherapy for malignant thymoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cycl | 1983 |
Combination chemotherapy in invasive thymoma role of COPP.
Topics: Adult; Aged; Antineoplastic Agents; Cyclophosphamide; Drug Administration Schedule; Drug Therapy, Co | 1980 |
Thymoma. A retrospective study of 87 cases.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Child; C | 1994 |
[Treatment of invasive thymoma using low dose and extended-field irradiation including hemi-thorax or whole-thorax].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modali | 1993 |
Nocardiosis after corticosteroid therapy for malignant thymoma.
Topics: Anti-Inflammatory Agents; Bacteremia; Humans; Hydrocortisone; Immunocompromised Host; Male; Middle A | 1993 |
Pancytopenia associated with thymoma resolving after thymectomy and immunosuppressive therapy. Case report.
Topics: Adult; Blood Transfusion; Cyclosporine; Female; Follow-Up Studies; Glucocorticoids; Humans; Immunosu | 1995 |
Successful treatment of a patient with a thymoma and pure red-cell aplasia with octreotide and prednisone.
Topics: Antineoplastic Agents, Hormonal; Drug Therapy, Combination; Female; Glucocorticoids; Humans; Middle | 1997 |
Myasthenia gravis: diagnosis and follow-up of 100 consecutive patients.
Topics: Age of Onset; Aged; Autoimmune Diseases; Azathioprine; Cholinesterase Inhibitors; Cohort Studies; Di | 1997 |
Dramatic response of postthymomectomy myasthenia gravis with multiple lung nodules to corticosteroids.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Therapy, Combination; Fem | 1997 |
Pemphigus erythematosus associated with thymoma: a case report.
Topics: Cicatrix; Dapsone; Drug Therapy, Combination; Humans; Male; Middle Aged; Pemphigus; Postoperative Co | 1999 |
Role of somatostatin analogue-based therapy in unresponsive malignant thymomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Male; Middle Aged; Neoplasm Staging; | 1999 |
Granulomatous myositis, primary biliary cirrhosis, pancytopenia, and thymoma.
Topics: Adult; Anti-Inflammatory Agents; Granuloma; Humans; Liver Cirrhosis, Biliary; Male; Muscle, Skeletal | 2000 |
Clinical characteristics and prognosis of myasthenia gravis in older people.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents; Azathioprine; Cholinesterase Inhibitors; Drug The | 2000 |
Regression of invasive thymoma following corticosteroid therapy.
Topics: Adult; Antineoplastic Agents, Hormonal; Humans; Male; Prednisone; Remission Induction; Thymoma; Thym | 2001 |
Treatment of myasthenia gravis. Report on 139 patients.
Topics: Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Adult; Female; Follow-Up Studies; Humans; Male | 1979 |
Polymyositis and dermatomyositis: clinical problems.
Topics: Collagen Diseases; Dermatomyositis; Diagnosis, Differential; Humans; Myasthenia Gravis; Myositis; Ne | 1978 |
"Disappearing" spinal cord compression: oncolytic effect of glucocorticoids (and other chemotherapeutic agents) on epidural metastases.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Dexamethasone; Dysgerminoma; Epidural Space; Humans; | 1977 |
Regression of malignant thymoma with metastases after treatment with adrenocortical steroids.
Topics: Female; Humans; Middle Aged; Neoplasm Metastasis; Prednisone; Thymoma; Thymus Neoplasms | 1978 |
[Remission of pure red cell aplasia obtained by splenectomy after failure of thymomectomy and immunosuppressive treatment].
Topics: Anemia, Aplastic; Anemia, Hemolytic, Autoimmune; Autoimmune Diseases; Erythropoiesis; Humans; Immuno | 1978 |
Invasive thymoma responsive to oral corticosteroids.
Topics: Administration, Oral; Humans; Male; Mediastinal Neoplasms; Middle Aged; Neoplasm Metastasis; Pleural | 1978 |
The role of suppressor cells in the pathogenesis of common variable hypogammaglobulinemia and the immunodeficiency associated with myeloma.
Topics: Agammaglobulinemia; Antibody Formation; Antibody-Producing Cells; B-Lymphocytes; Cell Differentiatio | 1976 |
Invasive thymoma and myasthenia gravis: a twenty-year experience.
Topics: Female; Humans; Male; Middle Aged; Myasthenia Gravis; Prednisone; Thymectomy; Thymoma; Thymus Neopla | 1975 |
Myasthenia gravis and invasive thymoma: a 20-year experience.
Topics: Adult; Aged; Chlorambucil; Cyclophosphamide; Female; Humans; Male; Middle Aged; Myasthenia Gravis; N | 1975 |
Malignant thymoma associated with peripheral T-cell lymphocytosis.
Topics: Adult; Aged; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modal | 1991 |
Myasthenia gravis.
Topics: Adult; Aged; Female; Humans; Male; Myasthenia Gravis; Prednisone; Thymoma | 1990 |
[Value of x-ray computed tomography in assessing the extent of invasive lympho-epithelial thymoma in the adult. Therapeutic implications].
Topics: Adrenal Cortex Neoplasms; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined | 1986 |
[Invasive thymoma with pulmonary metastasis. Complete remission 5 years after surgery and chemotherapy using the CHOP-BLEO protocol].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubicin | 1988 |
Chemotherapy of invasive thymoma. A retrospective study of 22 cases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Combined Modality | 1989 |
Disseminated thymoma and myasthenia gravis: dramatic response to prednisone.
Topics: Combined Modality Therapy; Female; Humans; Middle Aged; Myasthenia Gravis; Neoplasm Metastasis; Pred | 1989 |
Chemotherapy of malignant thymoma. Case report and review of the literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Doxorubicin; Etoposide; | 1986 |
[Successful chemotherapy of a metastatic malignant thymoma].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cyclophosphamide; Female; Hum | 1987 |
High-dose intravenous immunoglobulin in the management of myasthenia gravis.
Topics: Adult; Aged; Autoantibodies; Blood Proteins; Drug Therapy, Combination; Female; Humans; Infusions, P | 1986 |
Chemotherapy in invasive thymomas: five case reports.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dacarbazine; Doxorubicin; Female; | 1986 |
[Full-dose CHOP chemotherapy--feasibility and influence upon radiotherapy].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; | 1985 |
Thymoma, myasthenia gravis, erythroblastopenic anemia and systemic lupus erythematosus in one patient.
Topics: Ambenonium Chloride; Anemia, Aplastic; Autoimmune Diseases; Bone Marrow; Bone Marrow Cells; Bronchop | 1973 |
Thymoma, acquired hypogammaglobulinaemia, lichen planus, alopecia areata.
Topics: Agammaglobulinemia; Aged; Alopecia Areata; Ampicillin; Blood Transfusion; Bronchiectasis; Cytotoxici | 1974 |
Erythroid aplasia following thymomectomy. Report of a case with a positive lupus erythematosus cell preparation and elevated plasma erythropoietin level.
Topics: Blood Transfusion; Bone Marrow; Erythropoiesis; Erythropoietin; Female; Humans; Mediastinal Neoplasm | 1966 |
Prolonged respirator support for the treatment of intractable myasthenia gravis.
Topics: Adrenocorticotropic Hormone; Antilymphocyte Serum; Drug Therapy, Combination; Enteral Nutrition; Fem | 1974 |
Pemphigus vulgaris and internal malignancy.
Topics: Adenocarcinoma, Scirrhous; Adult; Aged; Breast Neoplasms; Carcinoma, Squamous Cell; Dexamethasone; F | 1974 |
Thymoma associated with pure red cell aplasia and hypogammaglobulinemia.
Topics: Agammaglobulinemia; Aged; Anemia, Aplastic; Blood Cell Count; Blood Transfusion; Bone Marrow Examina | 1973 |
Response of thymoma to steroids.
Topics: Aged; Female; Humans; Mediastinal Neoplasms; Prednisone; Radiography; Thoracic Surgery; Thorax; Thym | 1974 |
Immunosurveillance and cancer: epidemiological evidence.
Topics: Adolescent; Adult; Age Factors; Aged; Azathioprine; Chediak-Higashi Syndrome; Child; Child, Preschoo | 1970 |
Thymoma associated with pancytopenia and Hashimoto's thyroiditis.
Topics: Adolescent; Anemia, Aplastic; Bone Marrow; Cobalt Isotopes; Female; Humans; Prednisone; Stanozolol; | 1972 |
[Anemia caused by erythroblastopenia in adult age].
Topics: Aged; Analgesics; Anemia, Aplastic; Azathioprine; Blood Transfusion; Female; Heart Failure; Hepatiti | 1970 |
Successful immunosuppressive treatment of erythroid aplasia appearing after thymectomy.
Topics: Anemia, Aplastic; Antibodies, Antinuclear; Azathioprine; Bone Marrow; Cyclophosphamide; Erythropoies | 1970 |
[Erythroblastophthisis in thymoma. Report on 2 observations with remission].
Topics: Anemia, Aplastic; Female; Humans; Male; Middle Aged; Nandrolone; Prednisone; Thymectomy; Thymoma | 1965 |